

UAB THE UNIVERSITY OF ALABAMA AT BIRMINGHAM

VEITH: IMPOSSIBLE
Connecting The Research Community

Prediction Of 1-Year Mortality After Endovascular TAAA Repair: When Should We NOT Offer The Procedure

Adam W. Beck, MD
Professor of Surgery
Division Director of Vascular Surgery and Endovascular Therapy


Disclosures

All proceeds to UAB

Consultant for:
Artivion, Cook Medical, Philips, Medtronic, Terumo Aortic

Research support: Cook Medical, Endospa, Medtronic, Philips, Terumo, W.L. Gore & Associates

UAB THE UNIVERSITY OF ALABAMA AT BIRMINGHAM DIVISION OF VASCULAR SURGERY & ENDOVASCULAR THERAPY




One Year Mortality after Repair in the US-ARC

- Prospectively maintained database consisting of all patients treated with Investigational Device Exemption F/BEVAR
- Physician-sponsored data from across 10 U.S. sites is independently monitored and continuously audited by the Food and Drug Administration (US-FDA)

United States F/BEVAR Aortic Research Consortium (ARC)

UAB THE UNIVERSITY OF ALABAMA AT BIRMINGHAM Division of Vascular Surgery and Endovascular Therapy



Results: Patient Demographics and Comorbidities



Table 4. Demographics by Extent Category

Demographic	Overall (N=2,099)	Complex AAA (N=709)	CE 1-3 (N=773)	CE 4-5 (N=517)	P-Value
Male	71.8%	81.8%	56.8%	79.4%	<0.001
White	87.8%	91.8%	84.9%	86.4%	<0.001
Age	73.8 +/- 8.0	75.0 +/- 7.3	72.1 +/- 8.7	74.6 +/- 7.42	<0.001
CAD	45.4%	52.4%	39.6%	52.1%	<0.001
CHF	12.2%	14.2%	10.5%	13.6%	0.08
CCPD	35.4%	37.8%	35.5%	32.4%	0.13
Home Oxygen	9.5%	8.4%	10.7%	8.4%	0.44
CVA	17.1%	16.5%	17.8%	16.8%	0.82
Diabetes	15.2%	17.1%	12.6%	16.2%	0.04
ESRD	1.7%	0.4%	2.6%	2.1%	0.004
HTN	91.7%	90.0%	91.8%	93.6%	0.07
Prior MI	31.1%	28.7%	35.6%	29.3%	<0.001
Current Smoker	29.0%	28.4%	27.8%	31.0%	0.45
Functional Status					0.07
Independent	91.2%	90.1%	90.4%	93.5%	
Partial Dependent	8.1%	8.8%	9.6%	5.9%	
Fully Dependent	0.6%	1.0%	0.0%	0.3%	
Connective Tissue Disorder	0.5%	0.0%	1.4%	0.0%	<0.001

UAB THE UNIVERSITY OF ALABAMA AT BIRMINGHAM Division of Vascular Surgery and Endovascular Therapy

Results: Prior Operative History/Preoperative Labs



Operative Variable	Overall (N=2,099)	Complex AAA (N=709)	CE 1-3 (N=770)	CE 4-5 (N=577)	P-Value
Preoperative Aneurysm Size	64.3 +/- 11.1 cm	62.6 +/- 12.0	66.1 +/- 10.5	64.4 +/- 10.2	<0.001
Prior Type B Dissection	6.0%	0	15.8%	2.1%	<0.001
Prior Type A Dissection	2.8%	0	8.5%	0.4%	<0.001
Prior TEVAR	13.2%	1.4%	29.9%	5.3%	<0.001
Prior EVAR	19.0%	28.1%	11.7%	19.2%	<0.001
Prior Open TAAA repair	2.1%	0.3%	3.1%	3.4%	<0.001
Prior Open AAA	11.4%	4.7%	13.1%	17.6%	<0.001
Prior Open Arch	4.0%	0.2%	3.7%	0.3%	<0.001
Preoperative Creatinine mg/dl	1.23 +/- 0.88	1.2 +/- 0.51	1.3 +/- 1.2	1.2 +/- 0.70	0.16
Preoperative Hematocrit	39.3 +/- 5.3	40.3 +/- 4.8	37.7 +/- 5.4	40.1 +/- 5.4	<0.001






Multivariable Risk Factors for One Year Mortality

Predictors of 1-Year Mortality: Adjusted Analysis by Cox Regression


Variable	Hazard Ratio	95% Confidence Interval	P-value
Current Smoker	1.583	1.195, 2.096	0.001
Creatinine > 1.7	1.446	1.035, 2.02	0.025
CHF	2.092	1.543, 2.825	<0.001
Max Diameter > 7 cm	1.678	1.276, 2.208	<0.001
Age > 75	1.837	1.41, 2.387	<0.001
Extent I-III	1.592	1.205, 2.102	0.001
COPD	1.33	1.028, 1.72	0.03
Anemic (Hematocrit < 36)	1.45	1.04, 2.02	<0.001






Conclusions/Future Directions:

- BFEVAR is excellent at preventing rupture after repair
- TAAA patients are often highly co-morbid, which can lead to early mortality after repair despite prevention of rupture
- Highly comorbid patients may not benefit from repair at smaller aneurysm diameter



UAB

Thank you!



United States Aortic Research Consortium
PS-IDE x 10

A Schauer
M Farber
M Sweet
G Oderich
C Timaran

A Lee
D Schneider
M Eagleton
W Gasper